130 related articles for article (PubMed ID: 12909563)
1. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
Lemahieu WP; Maes BD; Ghoos Y; Rutgeerts P; Verbeke K; Vanrenterghem Y
Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G470-82. PubMed ID: 12909563
[TBL] [Abstract][Full Text] [Related]
2. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients.
Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem YF
Kidney Int; 2004 Jul; 66(1):433-40. PubMed ID: 15200453
[TBL] [Abstract][Full Text] [Related]
3. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation.
Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem Y
Kidney Int; 2005 Mar; 67(3):1152-60. PubMed ID: 15698457
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.
Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem Y
Am J Transplant; 2004 Sep; 4(9):1514-22. PubMed ID: 15307840
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
6. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
7. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
[TBL] [Abstract][Full Text] [Related]
8. Mdr1 limits CYP3A metabolism in vivo.
Lan LB; Dalton JT; Schuetz EG
Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
[TBL] [Abstract][Full Text] [Related]
9. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
Krivoruk Y; Kinirons MT; Wood AJ; Wood M
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):608-14. PubMed ID: 7995002
[TBL] [Abstract][Full Text] [Related]
11. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
Lown KS; Bailey DG; Fontana RJ; Janardan SK; Adair CH; Fortlage LA; Brown MB; Guo W; Watkins PB
J Clin Invest; 1997 May; 99(10):2545-53. PubMed ID: 9153299
[TBL] [Abstract][Full Text] [Related]
12. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification.
Chan LM; Cooper AE; Dudley AL; Ford D; Hirst BH
J Drug Target; 2004; 12(7):405-13. PubMed ID: 15621665
[TBL] [Abstract][Full Text] [Related]
14. Erythromycin breath test and clinical transplantation.
Watkins PB
Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
[TBL] [Abstract][Full Text] [Related]
15. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
[TBL] [Abstract][Full Text] [Related]
16. Effects of uptake and efflux transporter inhibition on erythromycin breath test results.
Frassetto LA; Poon S; Tsourounis C; Valera C; Benet LZ
Clin Pharmacol Ther; 2007 Jun; 81(6):828-32. PubMed ID: 17361125
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.
Lemahieu W; Maes B; Verbeke K; Rutgeerts P; Geboes K; Vanrenterghem Y
Am J Transplant; 2005 Jun; 5(6):1383-91. PubMed ID: 15888045
[TBL] [Abstract][Full Text] [Related]
18. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study.
de Wildt SN; Berns MJ; van den Anker JN
Ther Drug Monit; 2007 Apr; 29(2):225-30. PubMed ID: 17417078
[TBL] [Abstract][Full Text] [Related]
19. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.
Dürr D; Stieger B; Kullak-Ublick GA; Rentsch KM; Steinert HC; Meier PJ; Fattinger K
Clin Pharmacol Ther; 2000 Dec; 68(6):598-604. PubMed ID: 11180019
[TBL] [Abstract][Full Text] [Related]
20. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]